Greatest risk for mortality seen with high blood pressure, glucose intolerance, and low high-density lipoprotein cholesterol
TUESDAY, Sept. 23, 2025 (HealthDay News) — For patients with metabolic dysfunction-associated steatotic liver disease (MASLD), the cardiometabolic risk factors (CMRFs) of high blood pressure, glucose intolerance, and low high-density lipoprotein (HDL) cholesterol harbor the greatest risk for mortality, according to a study published online Sept. 17 in Clinical Gastroenterology and Hepatology.
Matthew Dukewich, M.D., Pharm.D., from the University of Southern California Keck School of Medicine in Los Angeles, and colleagues examined the association of individual CMRFs with all-cause mortality in U.S. adults with MASLD. A total of 21,872 adults ages 20 years and older with a Fatty Liver Index >60 and at least one CMRF were included in the study.
The researchers found that the participants had a mean body mass index (BMI) of 33.6 kg/m2 with a median of three CMRFs. Significant risks for mortality were seen for high blood pressure (adjusted hazard ratio [aHR], 1.39), glucose intolerance (aHR, 1.26), and low HDL cholesterol (aHR, 1.15) in an adjusted analysis of individual CMRFs. Compared with those with a BMI ≥25 to ≤30 kg/m2, mortality risk was significantly greater for BMI ≥35 to ≤40, ≥40 to ≤45, and ≥45 kg/m2. The number of CMRFs was associated with greater mortality risk in an age-adjusted analysis.
“MASLD is a complicated disease, and this study sheds new light on where doctors may want to focus their efforts when treating patients,” senior author Norah A. Terrault, M.D., also from the University of Southern California Keck School of Medicine, said in a statement.
Abstract/Full Text (subscription or payment may be required)
Onset of Mortality, Morbidity Delayed for Offspring of Centenarians
Antenatal Complications Increased With Maternal Multiple Long-Term Conditions
Phthalates From Personal Care Products Tied to Higher BP in Pregnancy
Increase Seen in Rates of Xenobiotic-Induced Liver Injury From 2020 to 2024
Impact of Alcohol Intake on Fibrosis Risk Varies by Sex, Liver Disease
Link Between Liver Fibrosis in MASLD, ASCVD Varies by Glycemic Status
Higher Coffee Consumption Linked to Favorable Indicators of Liver Health
Stepped Alcohol Treatment Via Telehealth Reduces Alcohol Use